Immunoglobulin light chain amyloidosis

Expert Review of Hematology

Volumn 7, Issue 1, 2014, Pages 143-156

  Merlini, Giampaolo ^a   Comenzo, Raymond L ^b   Seldin, David C ^c,d   Wechalekar, Ashutosh ^e   Gertz, Morie A ^f  

^a UNIVERSITY OF PAVIA   (Italy)

^b TUFTS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f MAYO CLINIC   (United States)

Author keywords

amyloid cardiomyopathy; biomarkers; novel agents; proteotoxicity

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; THALIDOMIDE;

AMYLOIDOSIS; BONE MARROW; CELL CLONE; CELL THERAPY; DIURETIC THERAPY; EARLY DIAGNOSIS; HEART INJURY; HUMAN; ORGAN TRANSPLANTATION; PLASMA CELL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TARGET ORGAN; TISSUE INJURY; TREATMENT RESPONSE;

AMYLOIDOSIS; DIURETICS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; ORGAN TRANSPLANTATION; RNA INTERFERENCE; STEM CELL TRANSPLANTATION;

EID: 84893279013     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.858594     Document Type: Review

References (111)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349(6), 583-596 (2003).
2. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N. Engl. J. Med. 323(8), 508-513 (1990).
3. Bodin K, Ellmerich S, Kahan MC et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468(7320), 93-97 (2010).
4. Li JP, Galvis ML, Gong F et al. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc. Natl Acad. Sci. USA 102(18), 6473-6477 (2005).
5. Motamedi-Shad N, Monsellier E, Torrassa S, Relini A, Chiti F. Kinetic analysis of amyloid formation in the presence of heparan sulfate: faster unfolding and change of pathway. J. Biol. Chem. 284(43), 29921-29934 (2009).
6. Ren R, Hong Z, Gong H et al. Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils. J. Biol. Chem. 285(48), 37672-37682 (2010).
7. Martin DJ, Ramirez-Alvarado M. Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction. Biophys. Chem. 158(1), 81-89 (2011).
8. Wall JS, Richey T, Stuckey A et al. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Proc. Natl Acad. Sci. USA 108(34), E586-E594 (2011).
9. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333-366 (2006).
10. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 121(26), 5124-5130 (2013).
11. Hayman SR, Bailey RJ, Jalal SM et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood 98(7), 2266-2268 (2001).
12. Bochtler T, Hegenbart U, Cremer FW et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 111(9), 4700-4705 (2008).
13. Bryce AH, Ketterling RP, Gertz MA et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 94(3), 380-386 (2009).
14. Zhou P, Hoffman J, Landau H, Hassoun H, Iyer L, Comenzo RL. Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis. Clin. Lymphoma Myeloma Leuk. 12(1), 49-58 (2012).
15. Bochtler T, Hegenbart U, Heiss C et al. Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood 117(14), 3809-3815 (2011).
16. Oliva L, Pengo N, Palladini G et al. Proteasome activity and stress in light chain amyloidosis. Amyloid 17(Suppl. 1), 99, Abstract OP-043 (2010).
17. Dispenzieri A, Seenithamby K, Lacy MQ et al. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant. 48(10), 1302-1307 (2013).
18. Comenzo RL, Fein DE, Hassoun H et al. Long-term outcomes of patients with systemic light chain amyloidosis (AL) treated at diagnosis with risk-adapted stem cell transplant and consolidation with novel agents. ASH Annual Meeting Abstracts 120(21), 3150 (2012).
19. Comenzo RL, Wally J, Kica G et al. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br. J. Haematol. 106(3), 744-751 (1999).
20. Perfetti V, Casarini S, Palladini G et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood 100(3), 948-953 (2002).
21. Perfetti V, Palladini G, Casarini S et al. The repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood 119(1), 144-150 (2012).
22. Prokaeva T, Spencer B, Kaut M et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum. 56(11), 3858-3868 (2007).
23. Liao R, Jain M, Teller P et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104(14), 1594-1597 (2001).
24. Brenner DA, Jain M, Pimentel DR et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ. Res. 94(8), 1008-1010 (2004).
25. Shi J, Guan J, Jiang B et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc. Natl Acad. Sci. USA 107(9), 4188-4193 (2010).
26. Shin JT, Ward JE, Collins PA et al. Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report. Amyloid 19(4), 191-196 (2012).
27. Mishra S, Guan J, Plovie E et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am. J. Physiol. Heart Circ. Physiol. 305(1), H95-H103 (2013).
28. Palladini G, Lavatelli F, Russo P et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107(10), 3854-3858 (2006).
29. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction- Alzheimer's disease of the heart? N. Engl. J. Med. 368(5), 455-464 (2013).
30. Herrera GA, Russell WJ, Isaac J et al. Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo. Ultrastruct. Pathol. 23(2), 107-126 (1999).
31. Keeling J, Herrera GA. Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage. Kidney Int. 68(4), 1590-1603 (2005).
32. Biolo A, Ramamurthy S, Connors LH et al. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circ. Heart Fail. 1(4), 249-257 (2008).
33. Tanaka K, Essick EE, Doros G et al. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. J. Am. Heart Assoc. 2(2), e005868 (2013).
34. Foli A, Palladini G, Caporali R et al. The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid 18(Suppl. 1), 80-82 (2011).
35. Soares SM, Fervenza FC, Lager DJ, Gertz MA, Cosio FG, Leung N. Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in patients. Am. J. Kidney Dis. 52(6), 1079-1083 (2008).
36. Schonland SO, Hegenbart U, Bochtler T et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of patients. Blood 119(2), 488-493 (2012).
37. Arbustini E, Morbini P, Verga L et al. Light and electron microscopy immunohistochemical characterization of amyloid deposits. Amyloid 4(3), 157-170 (1997).
38. Brambilla F, Lavatelli F, Di Silvestre D et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 119(8), 1844-1847 (2012).
39. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114(24), 4957-4959 (2009).
40. Palladini G, Russo P, Bosoni T et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin. Chem. 55(3), 499-504 (2009).
41. Lachmann HJ, Gallimore R, Gillmore JD et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br. J. Haematol. 122(1), 78-84 (2003).
42. Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am. Soc. Hematol. Educ. Program 2010, 287-294 (2010).
43. Palladini G, Dispenzieri A, Gertz MA et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J. Clin. Oncol. 30(36), 4541-4549 (2012).
44. Buss SJ, Emami M, Mereles D et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J. Am. Coll. Cardiol. 60(12), 1067-1076 (2012).
45. Banypersad SM, Sado DM, Flett AS et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ. Cardiovasc. Imaging 6(1), 34-39 (2013).
46. Rapezzi C, Quarta CC, Guidalotti PL et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc. Imaging 4(6), 659-670 (2011).
47. Merlini G, Seldin DC, Gertz M.A. Amyloidosis: pathogenesis and new therapeutic options. J. Clin. Oncol. 29(14), 1924-1933 (2011).
48. Cordes S, Dispenzieri A, Lacy MQ et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer 118(24), 6105-6109 (2012).
49. Lebovic D, Hoffman J, Levine BM et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br. J. Haematol. 143(3), 369-373 (2008).
50. Dietrich S, Schonland SO, Benner A et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 116(4), 522-528 (2010).
51. Gertz MA, Dispenzieri A. Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials. Oncology (Williston Park) 26(2), 152-161 (2012).
52. Kastritis E, Anagnostopoulos A, Roussou M et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 92(10), 1351-1358 (2007).
53. Mikhael JR, Schuster SR, Jimenez-Zepeda VH et al. Cyclophosphamide- bortezomibdexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 119(19), 4391-4394 (2012).
54. Leung N, Leung TR, Cha SS, Dispenzieri A, Lacy MQ, Gertz M.A. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood 106(10), 3353-3357 (2005).
55. Palladini G, Russo P, Foli A et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann. Hematol. 91(1), 89-92 (2012).
56. Comenzo RL, Reece D, Palladini G et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26(11), 2317-2325 (2012).
57. Tsai SB, Seldin DC, Quillen K et al. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood 120(22), 4445-4446 (2012).
58. Jaccard A, Moreau P, Leblond V et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N. Engl. J. Med. 357(11), 1083-1093 (2007).
59. Comenzo RL. How I treat amyloidosis. Blood 114(15), 3147-3157 (2009).
60. Palladini G, Perfetti V, Obici L et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103(8), 2936-2938 (2004).
61. Landau H, Hassoun H, Rosenzweig MA et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 27(4), 823-828 (2013).
62. Reece DE, Hegenbart U, Sanchorawala V et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 118(4), 865-873 (2011).
63. Dispenzieri A, Lacy MQ, Rajkumar SV et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 10(4), 257-261 (2003).
64. Cohen AD, Zhou P, Chou J et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br. J. Haematol. 139(2), 224-233 (2007).
65. Sanchorawala V, Wright DG, Rosenzweig M et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 109(2), 492-496 (2007).
66. Shah Gl KE, Fallo S, Cossor Fi, Smith H, Klein Ak, Miller Kb, Comenzo Rl. Subcutaneous bortezomib in combination regimens in newly diagnosed patients with myeloma or systemic AL amyloidosis: high response rates and minimal toxicity Blood (ASH Annual Meeting Abstracts) 120, 2968 (2012).
67. Specter R, Sanchorawala V, Seldin DC et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol. Dial. Transplant. 26(3), 881-886 (2011).
68. Tapan U, Seldin DC, Finn KT et al. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood 116(23), 5071-5072 (2010).
69. Gertz M.A. I don't know how to treat amyloidosis. Blood 116(4), 507-508 (2010).
70. Kastritis E, Wechalekar AD, Dimopoulos MA et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J. Clin. Oncol. 28(6), 1031-1037 (2010).
71. Gertz M, Lacy M, Dispenzieri A et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk. Lymphoma 49(1), 36-41 (2008).
72. Gertz MA, Lacy MQ, Dispenzieri A et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 48(4), 557-561 (2013).
73. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 110(10), 3561-3563 (2007).
74. Madan S, Kumar SK, Dispenzieri A et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 119(5), 1117-1122 (2012).
75. Palladini G, Russo P, Nuvolone M et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 110(2), 787-788 (2007).
76. Moreau P, Jaccard A, Benboubker L et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 116(23), 4777-4782 (2010).
77. Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica 98(5), 789-792 (2013).
78. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109(2), 457-464 (2007).
79. Dispenzieri A, Lacy MQ, Zeldenrust SR et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109(2), 465-470 (2007).
80. Sanchorawala V, Finn KT, Fennessey S et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood 116(11), 1990-1991 (2010).
81. Kumar SK, Hayman SR, Buadi FK et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 119(21), 4860-4867 (2012).
82. Palladini G, Russo P, Foli A et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann. Hematol. 91(1), 89-92 (2012).
83. Dispenzieri A, Dingli D, Kumar SK et al. Discordance between serum cardiac biomarker and immunoglobulin-free lightchain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am. J. Hematol. 85(10), 757-759 (2010).
84. Dispenzieri A, Buadi F, Laumann K et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 119(23), 5397-5404 (2012).
85. Reece DE, Sanchorawala V, Hegenbart U et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 114(8), 1489-1497 (2009).
86. Bockorny M, Chakravarty S, Schulman P, Bockorny B, Bona R. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Acta Haematol. 128(4), 244-247 (2012).
87. Dubrey SW, Reece DE, Sanchorawala V et al. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM 104(11), 957-970 (2011).
88. Benson MD, Kluve-Beckerman B, Zeldenrust SR et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 33(5), 609-618 (2006).
89. Ackermann EJ, Guo S, Booten S et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 19(Suppl. 1), 43-44 (2012).
90. Hovey BM, Ward JE, Soo Hoo P, O'hara CJ, Connors LH, Seldin DC. Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther. 18(12), 1150-1156 (2011).
91. Hrncic R, Wall J, Wolfenbarger DA et al. Antibody-mediated resolution of light chain-associated amyloid deposits [In Process Citation]. Am. J. Pathol. 157(4), 1239-1246 (2000).
92. Solomon A, Weiss DT, Wall JS. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11- 1F4. Clin. Cancer Res. 9(10 Pt 2), 3831S-3838S (2003).
93. Merlini G, Ascari E, Amboldi N et al. Interaction of the anthracycline 4'-iodo-4'- deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc. Natl Acad. Sci. USA 92(7), 2959-2963 (1995).
94. Gertz MA, Lacy MQ, Dispenzieri A et al. A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid 9(1), 24-30 (2002).
95. Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J. 20(2), 234-239 (2006).
96. Kristen AV, Dengler TJ, Hegenbart U et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 5(2), 235-240 (2008).
97. Swiecicki PL, Edwards BS, Kushwaha SS, Dispenzieri A, Park SJ, Gertz M.A. Left ventricular device implantation for advanced cardiac amyloidosis. J. Heart Lung Transplant. 32(5), 563-568 (2013).
98. Tang W, Mcdonald SP, Hawley CM et al. End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. Nephrol. Dial. Transplant. 28(2), 455-461 (2013).
99. Herrmann SM, Gertz MA, Stegall MD et al. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol. Dial. Transplant. 26(6), 2032-2036 (2011).
100. Dey BR, Chung SS, Spitzer TR et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation 90(8), 905-911 (2010).
101. Estep JD, Bhimaraj A, Cordero-Reyes AM, Bruckner B, Loebe M, Torre-Amione G. Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management. Methodist Debakey Cardiovasc. J. 8(3), 8-16 (2012).
102. Lonial S, Vij R, Harousseau JL et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J. Clin. Oncol. 30(16), 1953-1959 (2012).
103. De Weers M, Tai YT, Van Der Veer MS et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186(3), 1840-1848 (2011).
104. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptortransduced T cells. Blood 119(12), 2709-2720 (2012).
105. Cibeira MT, Sanchorawala V, Seldin DC et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 118(16), 4346-4352 (2011).
106. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S. Transplantation for amyloidosis. Curr. Opin. Oncol. 19(2), 136-141 (2007).
107. Mangatter A, Schoenland SO, Hansberg M et al. Improvement of long-term survival after high-dose melphalan in patients with light chain amyloidosis responding to induction chemotherapy. ASH Annual Meeting Abstracts 112(11), 3334 (2008).
108. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N. Engl. J. Med. 336(17), 1202-1207 (1997).
109. Dhodapkar MV, Hussein MA, Rasmussen E et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 104(12), 3520-3526 (2004).
110. Reece De HU, Sanchorawala V, Merlini G et al. Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients with relapsed systemic light-chain (AL) amyloidosis. J. Clin. Oncol. 31(Suppl.), Abstract 8545 (2012).
111. Mikhael JR, Schuster SR, Jimenez-Zepeda VH et al. Cyclophosphamide- bortezomibdexamethasone (CyBorD) produces rapid and complete hematologic response in patients with ALamyloidosis. Blood 119(19), 4391-4394 (2012). ClinicalTrials.gov identifier: NCT01707264. http://clinicaltrials.gov/show/ NCT01707264